Grifols SA is a low-risk pharmaceutical company based in Spain with an ESG score of 15.1. Specializing in plasma-derived products, Grifols collects and manufactures plasma to be sold worldwide. With strategic acquisitions like Talecris and Biotest, Grifols has expanded its biopharma business significantly. In addition to a diverse portfolio of plasma-derived products, Grifols also operates in diagnostics and biosupplies.